New Developments in the Use of Immunotherapy for the Treatment of Advanced or Metastatic Cutaneous Squamous Cell Carcinoma | Supplements And Featured Publications

Dr. Milhem on Design of Phase 1b/2 Study With AST-008 in CSCC

August 13, 2020

Mohammed M. Milhem, MBBS, discusses the design of an open-label, multicenter phase 1b/2 dose escalation/expansion study with AST-008 in combination with a PD-1 inhibitor, such as pembrolizumab or cemiplimab, in Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Longer Follow-Up Data Confirms Cemiplimab’s Utility in CSCC, Though Challenges Remain

August 07, 2020

Anna C. Pavlick, DO, discusses the benefit of cemiplimab for patients with cutaneous squamous cell carcinoma (CSCC), the impact of these longer follow-up data, rare, but notable, toxicities that can arise with the agent, and ongoing research efforts aimed at increasing responses to immunotherapy in the CSCC space.

x